Optinose_logo_RGB.png
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
18 janv. 2024 12h00 HE | Optinose, Inc.
XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 Clinical Trials (ReOpen1 and...
Optinose_logo_RGB.png
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
06 sept. 2022 12h00 HE | Optinose, Inc.
YARDLEY, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose_logo_RGB.png
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
11 août 2022 07h00 HE | Optinose, Inc.
Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis...
Optinose_logo_RGB.png
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
13 juil. 2022 07h00 HE | Optinose, Inc.
XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from the landmark...
Optinose_logo_RGB.png
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
08 juil. 2022 07h00 HE | Optinose, Inc.
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from...
Optinose_logo_RGB.png
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
13 juin 2022 07h00 HE | Optinose, Inc.
First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients Physicians Diagnose Chronic Sinusitis 10 Times...
Optinose_logo_RGB.png
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
08 mars 2022 07h00 HE | Optinose, Inc.
Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects...
Optinose_logo_RGB.png
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
07 mars 2022 07h00 HE | Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...